MedTrace Logo

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT05338892 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 595

Last updated 2023-10-19

No results posted yet for this study

Summary

Primary Objective:

To evaluate objective response rate (ORR) in adult patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) who receive systemic treatment after at least 2 prior systemic therapies in the real-world setting according to Lugano classification of malignant lymphoma (Cheson, 2014) and as assessed by independent central review

Secondary Objectives:

To evaluate the following outcomes in adult patients with r/r DLBCL who are treated with currently available therapies in the real-world setting:

1. ORR according to Lugano classification and as assessed by treating physician evaluation
2. Complete Response (CR) rate according to Lugano classification and as assessed by:

* Independent central review, and
* Treating physician evaluation
3. Progression Free Survival (PFS) according to Lugano classification and as assessed by:

* Independent central review, and
* Treating physician evaluation
4. Overall Survival (OS)
5. Duration of response (DOR) according to Lugano classification and as assessed by

* Independent central review and
* Treating physician evaluation
6. Disease control rate (DCR) according to Lugano classification and as assessed by:

* Independent central reviewed
* Treating physician evaluation
7. Time to next treatment (TTNT)

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

OTHER

Non-Interventional

No study treatment will be administered on this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2023-10-05
Completion
2023-10-05

Countries

  • Austria
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05338892 on ClinicalTrials.gov